REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Latest posts by GlobeNewswire (see all)
- Start of construction of the fourth stage of the Vilneles Skverai residential project (Vilnius, Lithuania) - April 22, 2025
- LHV Group unaudited financial results for Q1 2025 - April 22, 2025
- Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years - April 22, 2025
